-
Mashup Score: 2
La acreditación premia la excelencia en la prestación del servicio de información a pacientes que sufren estas patologías.
Source: gacetamedica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Location, location, location: Protein kinase nanoclustering for optimised signalling output - 6 day(s) ago
This article reviews the latest studies that have used super-resolution microscopy and cluster analysis methodologies to study the mechanism of protein kinase signalling hubs and their organisation at nanoscale.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Frontiers | A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma - 16 day(s) ago
In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoi…
Source: www.frontiersin.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
Prostate Cancer and Prostatic Diseases – Application of next-generation imaging in biochemically recurrent prostate cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Location, location, location: Protein kinase nanoclustering for optimised signalling output - 20 day(s) ago
This article reviews the latest studies that have used super-resolution microscopy and cluster analysis methodologies to study the mechanism of protein kinase signalling hubs and their organisation at nanoscale.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Ken Herrmann on LinkedIn: Novartis confirms plans to file for Pluvicto® pre-taxane label expansion… - 21 day(s) ago
PSMAFORE UPDATE: OS hazard ratio less than 1.0 (HR<1.0) in the intent-to-treat (ITT) population unadjusted for cross-over. This is excellent for patients and…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated an
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35
Mitochondrial RNAs attach to chromatin and regulate nuclear transcription in endothelial stress response.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer - 1 month(s) ago
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modality in cancer treatment over recent years.
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients - 1 month(s) ago
Author links open overlay panel Faisal S. BinHumaid a b, Anshita Goel a, Naheema S. Gordon a, Ben Abbotts a, K.K. Cheng c, Maurice P. Zeegers d, Nicholas D. James e, Waleed M. Altaweel f, Raouf M. Seyam f, Brian F. Meyer b, Roland Arnold a, Douglas G. Ward a †, Richard T. Bryan a † There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
👏👏 El Servicio de Farmacia del Hospital 12 de Octubre recibe el Sello de Calidad en la Gestión de la Información al paciente Onco-hematológico - Gaceta Médica 😊 un placer trabajar con ellos! Siempre x delante los pts! @_SEOM @sefh_ https://t.co/zvwzEaN334